Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

February 28, 2024

https://www.globenewswire.com/news-release/2024/02/28/2837048/0/en/Virios-Therapeutics-Issues-Shareholder-Letter-Highlighting-Corporate-Progress-and-Key-Upcoming-Milestones.html

ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq:VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today issued a Shareholder Letter highlighting the Company’s progress and key milestones in 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Follow Us on Social Media

Sign Up for Our Newsletter

A RUM and AI, Please

Midday Market Dispatch- From Eco‑Boards to AI Batteries

Market Spotlight: APLD Powers AI, KDK Rolls Out, FICO Reinvents Scoring—And VENU Amplifies the Concert Economy

Kraig Labs Unlocks Spider Silk at Scale, Solving a Historical Problem for Nature’s Toughest Fiber

VENU Leads the Intimate Concert Trend with Boutique Venue Solutions

Follow Us on Social Media

Sign Up for Our Newsletter